Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: Immune phenomena or drug toxicity?
- 1 June 1995
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 34 (3) , 213-219
Abstract
The application of recombinant colony stimulating factors for chemotherapy induced granulocytopenia is becoming common in clinical oncology. Here we report on localized cutaneous side effects after subcutaneous administration of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in 11 patients with breast cancer receiving cytostatic treatment. Seven patients suffering from inflammatory breast cancer received cytostatic chemotherapy with mitoxantrone/cyclophosphamide, whereas four patients suffering from noninflammatory breast cancer received high-dose epirubicin/cyclophosphamide, respectively. rh GM-CSF was applicated subcutaneously in a dose of 5 µg/kg/d for at least ten days. In all patients, sharply demarked, maculous itching and burning erythemas restricted to the injection sites occured after three to four injections of rh GM-CSF. These eruptions cleared within 2 to 3 weeks, but reappeared after reexposure to rh GM-CSF. In contrast to previous sporadic reports, no generalized erythemas were observed. Because of this unexpected and subjectively intolerable side effect, rh GM-CSF administration had to be interrupted in all patients. Histopathological findings revealed skin infiltration with lymphocytes, monocytes/macrophages, neutrophils, and occasionally eosinophils, respectively. Since GM-CSF is known to alter immune functions, it seems likely that the eruptions were at least in part due to local immune reactions.Keywords
This publication has 39 references indexed in Scilit:
- GM-CSF therapy and capillary-leak syndromeAnnals of Hematology, 1991
- New Concepts of IgE RegulationInternational Archives of Allergy and Immunology, 1991
- Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.Journal of Clinical Investigation, 1990
- LEUCOCYTOCLASTIC VASCULITIS DURING GM‐CSF THERAPYBritish Journal of Haematology, 1989
- Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophoresNature, 1989
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced MyelosuppressionNew England Journal of Medicine, 1988
- Keratinocyte Derived T-Cell Growth Factor (KTGF) Is Identical to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)Journal of Investigative Dermatology, 1988
- B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cellsCell, 1987
- Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes.Journal of Clinical Investigation, 1986
- Purified Human Granulocyte-Macrophage Colony-Stimulating Factor: Direct Action on NeutrophilsScience, 1984